Cargando…
Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma
Hippo/YAP1 signaling is a major regulator of organ size, cancer stemness, and aggressive phenotype. Thus, targeting YAP1 may provide a novel therapeutic strategy for tumors with high YAP1 expression in esophageal cancer (EC). Chromatin immunoprecipitation (ChiP) and quantitative ChiP‐PCR were used t...
Autores principales: | Song, Shumei, Li, Yuan, Xu, Yan, Ma, Lang, Pool Pizzi, Melissa, Jin, Jiankang, Scott, Ailing W, Huo, Longfei, Wang, Ying, Lee, Jeffrey H., Bhutani, Manoop S., Weston, Brian, Shanbhag, Namita D, Johnson, Randy L., Ajani, Jaffer A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266288/ https://www.ncbi.nlm.nih.gov/pubmed/32175692 http://dx.doi.org/10.1002/1878-0261.12667 |
Ejemplares similares
-
Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors
por: Ajani, Jaffer A, et al.
Publicado: (2018) -
An improved strategy for CRISPR/Cas9 gene knockout and subsequent wildtype and mutant gene rescue
por: Jin, Jiankang, et al.
Publicado: (2020) -
Hippo pathway coactivators Yap and Taz are required to coordinate mammalian liver regeneration
por: Lu, Li, et al.
Publicado: (2018) -
LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma
por: Xu, Yan, et al.
Publicado: (2019) -
Correction to: LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma
por: Xu, Yan, et al.
Publicado: (2021)